TMS Co., Ltd. (TYO:4891)

Market Cap	5.71B -17.4%
Revenue (ttm)	n/a
Net Income	-700.90M
EPS	-15.99
Shares Out	45.67M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	521,100
Open	126.00
Previous Close	125.00
Day's Range	120.00 - 129.00
52-Week Range	92.00 - 166.00
Beta	0.53
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 9, 2026

About TMS Co., Ltd.

TMS Co., Ltd. engages in the research and development, manufacture, and sale of drug products, quasi-drugs, drug substances, medical devices, and medical commodities. The company is developing TMS-007, a stachybotrys microspora triprenyl phenol (SMTP) congener with prothrombolytic and anti-inflammatory/antioxidative activities, which has completed Phase 2a clinical trials for acute ischemic stroke treatment; and TMS-008, an SMTP congener with anti-inflammatory/antioxidative activities under nonclinical development for inflammatory complications...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 18
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4891

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 16, 2026

Data Sources Report a data error